Many serious health conditions can strike without warning.
1 in 4
heart attack patients have
no known risk factors [1]
1 in 5
stroke patients have
no known risk factors [2]
1 in 3
leukemia cases are diagnosed
in the emergency room [3]
CardioHemeRISK is a next-generation sequencing (NGS) blood test. The test detects clonal hematopoiesis (CH) mutations using Lucence’s mirror barcoding technology.
Available internationally outside the USA.
What is CH?
Clonal hematopoiesis (CH) is a common disorder acquired as a age- and lifestyle- related inflammatory process.
It starts typically above age 40 when one blood stem cell develops a mutation and begins making lots of blood cells (clonal expansion) with the same mutation. It is not cancer.
.png)
Compared to the general population, individuals with CH face higher risk:
12x
Heart Attack [4]
3.1x
Stroke [5]
12.9x
Leukemia [6]
CardioHemeRISK is recommended for:
-
Healthy individuals aged above 40 and below 80
-
Cancer survivors previously treated with chemotherapy or radiation
-
Individuals with history of atherosclerotic disease such as coronary artery disease or ischemic stroke
-
Healthy individuals aged above 40 with additional risk factors for atherosclerotic disease such as family history, hypertension, hyperlipidemia
Downloads
References:
-
Paul, G. et al. Global Heart 2023; 18(1): doi: 10.5334/gh.1189.
-
Beharry, J. et al. Eur Stroke J 2025; doi: 10.1177/23969873241309516.
-
Leukaemia Care. Leukaemia UK. Published September 4, 2022. Accessed May 2, 2025. https://www.leukaemiauk.org.uk/news/worrying-numbers-ofleukaemia-patients/.
-
Jaiswal, S. et al. N Engl J Med 2017; 377(2): 111-121. PMID: 28636844. Early onset myocardial infarction: HR = 12; 95% CI, 3.8–38; P < 0.001.
-
Jaiswal, S. et al. N Engl J Med 2014; 371(26): 2488-2498. PMID: 25426837. Ischemic stroke: HR = 3.1; 95% CI, 1.2–8.4; P = 0.025.
-
Genovese, G. et al. N Engl J Med 2014; 371: 2477-2487. PMID: 25426838. Hematologic cancer: HR = 12.9; 95% CI, 5.8–28.7; P < 0.001.
